Press Releases

There are currently no events to display.


July 22, 2021	Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
July 1, 2021	Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
June 24, 2021	Adverum Announces Changes to Management Team
June 1, 2021	Adverum Appoints CMO and CSO
May 12, 2021	Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
May 10, 2021	Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
May 6, 2021	Adverum Reports First Quarter 2021 Results
May 1, 2021	Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
April 28, 2021	Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
April 22, 2021	Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
April 21, 2021	Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
April 16, 2021	Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
April 15, 2021	Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
March 30, 2021	Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
March 18, 2021	Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 17, 2021	Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
March 1, 2021	Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results
February 22, 2021	Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
February 22, 2021	Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
February 18, 2021	Adverum Appoints Christopher J. DeRespino as Chief Business Officer
February 10, 2021	Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting
February 2, 2021	Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy
January 11, 2021	Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
January 7, 2021	Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
January 5, 2021	Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference
December 14, 2020	Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
November 23, 2020	Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference
November 14, 2020	Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
November 5, 2020	Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results
October 20, 2020	Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual
September 15, 2020	Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science
September 10, 2020	Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
August 18, 2020	Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock
August 12, 2020	Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
August 11, 2020	Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock
August 10, 2020	Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results
July 29, 2020	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 21, 2020	Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
July 13, 2020	Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)
July 6, 2020	Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD
June 25, 2020	Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing
June 15, 2020	Adverum Biotechnologies Announces Leadership Transition
June 4, 2020	Adverum Biotechnologies to Participate in Goldman Sachs 41st Annual Global Healthcare Conference
May 28, 2020	Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results
May 21, 2020	Adverum Biotechnologies to Host a Conference Call and Webcast to Report First Quarter 2020 Financial Results and Provide Corporate Update
May 4, 2020	Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
April 30, 2020	Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO
April 27, 2020	Adverum Biotechnologies to Host a Conference Call and Webcast to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD
April 27, 2020	Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
April 20, 2020	Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors
March 12, 2020	Adverum Biotechnologies Reports Recent Business Progress and Fourth Quarter 2019 Financial Results
March 11, 2020	Adverum Biotechnologies Announces Data Presentations at ARVO 2020
March 5, 2020	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
February 25, 2020	Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer
February 19, 2020	Adverum Biotechnologies to Present at Upcoming Investor Conferences
February 14, 2020	Adverum Biotechnologies Announces Closing of $150 Million Public Offering of Common Stock
February 11, 2020	Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
February 10, 2020	Adverum Biotechnologies Announces $100 Million Public Offering of Common Stock
February 8, 2020	Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020
January 28, 2020	Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting
January 27, 2020	Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA
January 12, 2020	Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook
January 11, 2020	Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting
December 18, 2019	Adverum Biotechnologies to Present at Upcoming Conferences
November 20, 2019	Adverum Biotechnologies to Participate in Piper Jaffray’s 31st Annual Healthcare Conference
November 7, 2019	Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results
October 31, 2019	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates
October 30, 2019	Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer
October 24, 2019	Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
October 23, 2019	Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress
October 11, 2019	Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
September 26, 2019	Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
September 12, 2019	Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD
September 4, 2019	Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting
August 28, 2019	Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
August 8, 2019	Adverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 1, 2019	Adverum Biotechnologies Announces Board and Senior Management Changes
July 25, 2019	Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates
July 15, 2019	Adverum Biotechnologies Appoints Senior Leaders
July 8, 2019	Adverum Biotechnologies to Present Data at Upcoming Conferences
June 10, 2019	Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD
May 16, 2019	Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD
May 8, 2019	Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 2, 2019	Adverum Biotechnologies Announces Board Changes
May 2, 2019	Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting
April 30, 2019	Adverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual Meeting
April 24, 2019	Adverum Biotechnologies Appoints Thomas Leung as Chief Financial Officer
April 16, 2019	Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO
April 15, 2019	Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
April 1, 2019	Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer
March 18, 2019	Adverum Biotechnologies to Participate in Upcoming Conferences
March 6, 2019	Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
February 28, 2019	Adverum to Present at the Cowen 39th Annual Health Care Conference
February 13, 2019	Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 11, 2019	Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
January 6, 2019	Adverum Biotechnologies Provides 2019 Outlook
December 20, 2018	Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
December 3, 2018	Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
December 3, 2018	Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
November 19, 2018	Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
November 13, 2018	Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference
November 8, 2018	Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 1, 2018	Adverum Biotechnologies Provides Program Updates
October 17, 2018	Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors
October 17, 2018	Adverum Biotechnologies Announces Data Presented at the European Society of Gene and Cell Therapy (ESGCT)
September 19, 2018	Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
September 18, 2018	Adverum to Present at Cantor Global Healthcare Conference
August 29, 2018	Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy to Treat Wet Age-related Macular Degeneration
August 24, 2018	Adverum Biotechnologies Receives Orphan Drug Designation for ADVM-053, a Novel Gene Therapy Candidate for the Treatment of Hereditary Angioedema
August 8, 2018	Adverum Biotechnologies Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 1, 2018	Adverum Biotechnologies Announces Clinical Progress Across Gene Therapy Pipeline
July 24, 2018	Adverum Biotechnologies Appoints Katherine Bock as Vice President, Investor Relations & Corporate Communications
June 4, 2018	Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference
May 17, 2018	Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st Annual Meeting
May 9, 2018	Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 3, 2018	Adverum Biotechnologies Announces Leadership Changes
May 1, 2018	Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD
March 6, 2018	Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update
February 26, 2018	Adverum Biotechnologies to Present at Upcoming Investor Conferences
February 26, 2018	Adverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 Gene Therapy for A1AT Deficiency
February 12, 2018	Adverum Biotechnologies Announces Closing of $69 Million Public Offering
February 8, 2018	Adverum Biotechnologies Announces Pricing of $60 Million Public Offering of Common Stock
February 7, 2018	Adverum Biotechnologies Announces Proposed Public Offering of Common Stock
January 25, 2018	Adverum Biotechnologies and Editas Medicine Extend Research Collaboration
January 4, 2018	Adverum Biotechnologies Provides 2018 Outlook
December 28, 2017	Adverum Biotechnologies Doses First Patient in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 for A1AT Deficiency
December 5, 2017	Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
November 15, 2017	Adverum Biotechnologies to Present at Upcoming Conferences
November 8, 2017	Adverum Biotechnologies Reports Third Quarter 2017 Financial Results and Provides Corporate Update
October 2, 2017	Adverum Biotechnologies Appoints Linda Neuman, M.D. as Vice President, Clinical Development
September 28, 2017	Adverum Biotechnologies to Present at Upcoming Conferences
September 27, 2017	Adverum Biotechnologies Presents Updated Preclinical Data on ADVM-022 in Wet AMD at the 2017 Targeting Ocular Disorders Conference
September 7, 2017	Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors
September 7, 2017	Adverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
August 8, 2017	Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update
June 20, 2017	Adverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer
May 22, 2017	Adverum Biotechnologies to Present at the Jefferies Global Healthcare Conference
May 10, 2017	Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings
May 9, 2017	Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update
April 20, 2017	Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
April 17, 2017	Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day
April 6, 2017	Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
March 14, 2017	Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors
March 6, 2017	Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update
February 21, 2017	Adverum Biotechnologies to Present at Upcoming Investor Conferences
January 18, 2017	Adverum Biotechnologies to Present At Phacilitate Cell & Gene Therapy World 2017
November 9, 2016	Adverum Biotechnologies to Present at Upcoming Investor Conferences
November 8, 2016	Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results
October 20, 2016	Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) Meeting
October 14, 2016	Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program
October 14, 2016	Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
October 13, 2016	Adverum Biotechnologies to Present at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
September 16, 2016	Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting
August 9, 2016	Adverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results
August 9, 2016	Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye
July 7, 2016	Adverum Biotechnologies Provides wet AMD Program Update
June 13, 2016	Adverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer
May 12, 2016	Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies
May 10, 2016	Avalanche Biotechnologies’ Stockholders Vote in Favor of Annapurna Transaction
May 6, 2016	Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results
April 27, 2016	Avalanche Biotechnologies to Present at Upcoming Scientific Meetings
March 3, 2016	Avalanche Biotechnologies Reports Fourth Quarter and Fiscal 2015 Financial Results
March 2, 2016	Avalanche Biotechnologies to Present at Upcoming Investor Conferences
February 1, 2016	Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger
November 20, 2015	Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO
November 9, 2015	Avalanche Biotechnologies, Inc. Reports Third Quarter 2015 Financial Results
August 13, 2015	Avalanche Biotechnologies, Inc. Reports Second Quarter 2015 Financial Results and Provides Update on AVA-101 Program
August 5, 2015	Avalanche Biotechnologies Awarded as Technology Pioneer by World Economic Forum
July 23, 2015	Avalanche Biotechnologies Announces Leadership Transition
June 15, 2015	Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration
May 14, 2015	Avalanche Biotechnologies Presents Three Posters at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 13, 2015	Avalanche Biotechnologies, Inc. Reports First Quarter 2015 Financial Results
April 28, 2015	Avalanche Biotechnologies to Present at Upcoming Scientific Meetings
March 25, 2015	Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness
March 18, 2015	Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015
March 5, 2015	Avalanche Biotechnologies, Inc. Reports Fourth Quarter and Fiscal 2014 Financial Results
February 25, 2015	Avalanche Biotechnologies to Present at Upcoming Investor Conferences
January 8, 2015	Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock
January 5, 2015	Avalanche Biotechnologies Announces Proposed Public Offering of Common Stock and Partial Release of Lock-Up Agreements in Connection Therewith
November 26, 2014	Avalanche Biotechnologies to Present at the 26th Annual Piper Jaffray Healthcare Conference
November 13, 2014	Avalanche Biotechnologies to Present at the Jefferies Global Healthcare Conference
November 12, 2014	Avalanche Biotechnologies, Inc. Reports Third Quarter 2014 Financial Results
October 30, 2014	Avalanche Biotechnologies to Participate in Nomura's Biotechnology Conference
October 9, 2014	Avalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting
October 1, 2014	Avalanche Biotechnologies to Participate in Gene Therapy Panel at the BIO Investor Forum
September 23, 2014	Avalanche Biotechnologies, Inc., Appoints Industry Leader Roman G. Rubio, M.D., as Senior Vice President and Head of Translational Medicine
September 19, 2014	Avalanche Biotechnologies to Present at the NewsMakers in the Biotech Industry Conference
September 11, 2014	Avalanche Biotechnologies, Inc. Reports Second Quarter 2014 Financial Results
August 5, 2014	Avalanche Biotechnologies Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares
July 31, 2014	Avalanche Biotechnologies Prices Initial Public Offering of $102.0 Million of Common Stock
July 1, 2014	Avalanche Biotechnologies Announces Appointment of Samuel B. Barone, M.D., as Chief Medical Officer
May 20, 2014	Avalanche Biotechnologies Announces Appointment of Industry Veteran Linda C. Bain as Chief Financial Officer
May 5, 2014	Regeneron and Avalanche Biotechnologies Announce Collaboration to Develop Next-Generation Gene Therapy Products in Ophthalmology
April 22, 2014	Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing
November 22, 2013	Avalanche Raises Additional Funding in Follow-On Financing
June 12, 2013	Avalanche’s Novel Technology Restores Vision in Pre-Clinical Models of Blindness
October 1, 2012	Avalanche Biotechnologies, Inc. Announced That it Has Been Awarded Two Grants from the National Eye Institute to Fund Pre-clinical Studies Related to its Novel AAV Variant Technology
May 16, 2012	Avalanche Biotechnologies, Inc. and Lonza Announce Global Manufacturing Collaboration for Adeno-associated Viral Vectors for Gene Therapy
November 1, 2011	Avalanche Announces Collaboration with Lions Eye Institute and Merck to Develop AVA-101

ADVM (Common Stock)
Exchange	NASDAQ (U.S. Dollar)
Price
Change (%)
Volume
Data as of 07/22/21 4:08 PM EDT
Copyright Nasdaq. Minimum 15 minutes delayed.

Investors

Press Releases

Keyword Search